Table 1.
The clinical information of the 13 SLE patients and 10 healthy people in our study.
| SLE (n = 13) | Healthy people (n = 10) | |
|---|---|---|
| Gender (female/male) | 11/2 | 9/1 |
| Age (year), median (range) | 38 (15-57) | 31 (26-37) |
| C3(g/L), median (range) | 0.76 (0.21-0.85) | N/A |
| C4(g/L), median (range) | 0.14 (0.03-0.28) | N/A |
| ANA(+) (percentage) | 13 (100%) | N/A |
| Anti-dsDNA(+) (percentage) | 10 (76.9%) | N/A |
| ANuA(+) (percentage) | 9 (69.2%) | N/A |
| Proteinuria (g/24 h), median (range) | 0.363 (0.045-10.98) | N/A |
| SLEDAI-2K, median (range) | 9 (6-21) | N/A |
| Rash (percentage) | 3 (23.1%) | N/A |
| Alopecia (percentage) | 2 (15.4%) | N/A |
| Fever (percentage) | 4 (30.8%) | N/A |
| Pleurisy (percentage) | 3 (23.1%) | N/A |
| Leukopenia (percentage) | 4 (30.8%) | N/A |
| Pericarditis (percentage) | 3 (23.1%) | N/A |
| Arthritis (percentage) | 2 (15.4%) | N/A |
| Organic encephalopathy syndrome (percentage) | 1 (7.7%) | N/A |
| Hematuria (percentage) | 1 (7.7%) | N/A |
| Thrombocytopenia (percentage) | 2 (15.4%) | N/A |
| Lupus headache (percentage) | 1 (7.7%) | N/A |
| Vasculitis (percentage) | 2 (15.4%) | N/A |
SLE, systemic lupus erythematosus; ANA, anti-nuclear antibody; Anti-dsDNA, anti-dsDNA antibodies; ANuA, anti-nucleosome antibodies; C3, Complement C3; C4, Complement C4; N/A, not applicable; SLEDAI-2K, SLE disease activity index 2000.